Eisai hit with Cancer Drugs Fund 'double Whammy'
This article was originally published in Scrip
Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.
You may also be interested in...
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.
Without further work, the EU-wide joint clinical assessments introduced by the EU regulation on health technology assessments will fail to meet the needs of advanced therapies, warns the Alliance for Regenerative Medicine.
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”